Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes.

Expert opinion on investigational drugs - 1 Jan 2016

Stahl Maximilian, Gore Steven D, Vey Norbert, Prebet Thomas

Abstract excerpt

INTRODUCTION: Epigenetic changes and mutations in epigenetic modifiers characterize and likely drive many cases of acute myeloid leukemia and myelodysplastic syndrome. Development of DNA methyltransferase inhibitors has been most successful in these diseases. While many epigenetic marks are potential targets of cancer therapies, histone deacetylase inhibitors (HDACi) have undergone the most advanced development...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Drug Design

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Epigenesis, Genetic

Share to Histone Deacetylase Inhibitors

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Myelodysplastic Syndromes

Share to Patient Selection

Source

Identifiers

PMID: 26807602
DOI: 10.1517/13543784.2016.1146251

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes.PMID 26807602Read ↗

Myelodysplastic Syndrome and Histone Deacetylase Inhibitors: “To Be or Not to Be Acetylated”?Semantic proximity Read ↗

Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemiaSemantic proximity Read ↗

Epigenetic Modifiers in Myeloid Malignancies: The Role of Histone Deacetylase InhibitorsSemantic proximity Read ↗

The evolution of epigenetic therapy in myelodysplastic syndromes and acute myeloid leukemia.Semantic proximity Read ↗

The epigenetic revolution in hematology: from benchside breakthroughs to clinical transformationsSemantic proximity Read ↗

Vorinostat in acute myeloid leukemia and myelodysplastic syndromesSemantic proximity Read ↗

Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignanciesSemantic proximity Read ↗

The evolving landscape of epigenetic target molecules and therapies in myeloid cancers: focus on acute myeloid leukemia and myeloproliferative neoplasmsSemantic proximity Read ↗

Epigenetic Therapy: Histone Acetylation, DNA Methylation and Anti-Cancer Drug DiscoverySemantic proximity Read ↗

Targeting DNA Methylation in Leukemia, Myelodysplastic Syndrome, and Lymphoma: A Potential Diagnostic, Prognostic, and Therapeutic ToolSemantic proximity Read ↗

HDAC Inhibitors in Acute Myeloid LeukemiaSemantic proximity Read ↗

Molecular Targeted Therapy and Immunotherapy for Myelodysplastic SyndromeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.